Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Nov 28 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release regarding its recent approval from the USFDA. The approval is for Levothyroxine Sodium for injection, which is indicated for treating myxedema coma. The drug will be manufactured at the company's facility in Jarod, India.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases